Surveillance after stopping treatment
| . | PIRR . | PEG-IFN-α/RBV . | ||||
|---|---|---|---|---|---|---|
| Start . | 18 mo . | 36 mo . | Start . | 18 mo . | 36 mo . | |
| Skin, n (%) | ||||||
| Purpura | 4 (18.2) | 6 (27.3) | 10 (45.4) | 5 (33) | 7 (47) | 10 (67) |
| Cutaneous ulcers | 1 (45) | 1 (4.5) | 2 (9) | 1 (6.7) | 2 (13.3) | 2 (13.3) |
| Musculoskeletal, n (%) | ||||||
| Weakness | 5 (22.7) | 7 (32) | 11 (50) | 5 (33) | 7 (47) | 10 (67) |
| Peripheral joint arthralgias | 4 (18.2) | 5 (23.5) | 9 (42.8) | 5 (33) | 6 (41.6) | 9 (60) |
| Peripheral nerves, n (%) | ||||||
| Sensitive/motor neuropathy | 2 (9) | 2 (9) | 3 (13.6) | 2 (13) | 3 (20) | 3 (20) |
| Renal involvement | ||||||
| Creatinine > 100 μM (%; mean ± SD) | 5 (141.3 ± 17.6) | 5 (185.5 ± 44.1) | 5 (203.1 ± 35.3) | 4 (159 ± 14.1) | 4 (194.3 ± 17.6) | 4 (185.5 ± 31.8) |
| Proteinuria > 0.25 g/24 h (%) (g/24 h; mean ± SD) | 1 (4.5; 2.5 ± 0.3) | 1 (4.5; 2.0 ± 0.2) | 1 (4.5; 2.9 ± 0.4) | 2 (13; 3.2 ± 0.9} | 2 (13; 2.5 ± 0.6) | 2 (13; 2.66 ± 0.54) |
| . | PIRR . | PEG-IFN-α/RBV . | ||||
|---|---|---|---|---|---|---|
| Start . | 18 mo . | 36 mo . | Start . | 18 mo . | 36 mo . | |
| Skin, n (%) | ||||||
| Purpura | 4 (18.2) | 6 (27.3) | 10 (45.4) | 5 (33) | 7 (47) | 10 (67) |
| Cutaneous ulcers | 1 (45) | 1 (4.5) | 2 (9) | 1 (6.7) | 2 (13.3) | 2 (13.3) |
| Musculoskeletal, n (%) | ||||||
| Weakness | 5 (22.7) | 7 (32) | 11 (50) | 5 (33) | 7 (47) | 10 (67) |
| Peripheral joint arthralgias | 4 (18.2) | 5 (23.5) | 9 (42.8) | 5 (33) | 6 (41.6) | 9 (60) |
| Peripheral nerves, n (%) | ||||||
| Sensitive/motor neuropathy | 2 (9) | 2 (9) | 3 (13.6) | 2 (13) | 3 (20) | 3 (20) |
| Renal involvement | ||||||
| Creatinine > 100 μM (%; mean ± SD) | 5 (141.3 ± 17.6) | 5 (185.5 ± 44.1) | 5 (203.1 ± 35.3) | 4 (159 ± 14.1) | 4 (194.3 ± 17.6) | 4 (185.5 ± 31.8) |
| Proteinuria > 0.25 g/24 h (%) (g/24 h; mean ± SD) | 1 (4.5; 2.5 ± 0.3) | 1 (4.5; 2.0 ± 0.2) | 1 (4.5; 2.9 ± 0.4) | 2 (13; 3.2 ± 0.9} | 2 (13; 2.5 ± 0.6) | 2 (13; 2.66 ± 0.54) |